189 related articles for article (PubMed ID: 11514167)
1. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
[TBL] [Abstract][Full Text] [Related]
2. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
[TBL] [Abstract][Full Text] [Related]
3. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
[TBL] [Abstract][Full Text] [Related]
4. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
[TBL] [Abstract][Full Text] [Related]
5. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
[TBL] [Abstract][Full Text] [Related]
6. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
Chen JM; Jin G; Sung A; Levin JI
Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
10. The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.
Tullis JS; Laufersweiler MJ; VanRens JC; Natchus MG; Bookland RG; Almstead NG; Pikul S; De B; Hsieh LC; Janusz MJ; Branch TM; Peng SX; Jin YY; Hudlicky T; Oppong K
Bioorg Med Chem Lett; 2001 Aug; 11(15):1975-9. PubMed ID: 11454461
[TBL] [Abstract][Full Text] [Related]
11. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
13. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
[TBL] [Abstract][Full Text] [Related]
14. N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.
Musso DL; Andersen MW; Andrews RC; Austin R; Beaudet EJ; Becherer JD; Bubacz DG; Bickett DM; Chan JH; Conway JG; Cowan DJ; Gaul MD; Glennon KC; Hedeen KM; Lambert MH; Leesnitzer MA; McDougald DL; Mitchell JL; Moss ML; Rabinowitz MH; Rizzolio MC; Schaller LT; Stanford JB; Tippin T; Warner JR; Whitesell LG; Wiethe RW
Bioorg Med Chem Lett; 2001 Aug; 11(16):2147-51. PubMed ID: 11514157
[TBL] [Abstract][Full Text] [Related]
15. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and identification of conformationally constrained selective MMP inhibitors.
Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
[TBL] [Abstract][Full Text] [Related]
17. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of highly selective MMP-13 inhibitors.
Li J; Rush TS; Li W; DeVincentis D; Du X; Hu Y; Thomason JR; Xiang JS; Skotnicki JS; Tam S; Cunningham KM; Chockalingam PS; Morris EA; Levin JI
Bioorg Med Chem Lett; 2005 Nov; 15(22):4961-6. PubMed ID: 16153831
[TBL] [Abstract][Full Text] [Related]
19. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
20. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
